Zimbabwe has rejected a significant US health deal worth $367m (272 million pounds) over five years because of the United States' request for confidential data.
The decision became public following a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
An official representative later clarified that the United States was seeking health data for scientific study and profit while refused to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more dialogue to find a deal agreeable to both sides so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court suspended a similar health funding agreement after legal challenges were raised about the security of Kenyans' health data.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to enhance transparency and accountability.
As per reports, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Put simply, our country would supply the raw materials for medical research without any certainty that the end products would be available to our population if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were upending structures previously set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This framework is designed to ensure that when a nation provides its data, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how future co-operation might be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but recommended that negotiations need to persist given that much of the nation's HIV programmes were funded by foreign aid.
"In cases where specific concerns exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it said.
This impasse underscores the continuing challenges between accepting vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.